Form SC 13G CytomX Therapeutics, Filed by: Flynn James E
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
CytomX Therapeutics (CTMX) Closes 7.67M Common Stock IPO at $12/Share
October 14, 2015 3:01 PM EDTCytomX Therapeutics, Inc. (Nasdaq: CTMX), a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, announced the closing of its initial public offering of 7,666,667 shares of common stock at an initial public offering price of $12.00 per share, before underwriting discounts and... More
